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Background: Mexico has been experiencing some of the most rapid shifts ever recorded in dietary and physical
activity patterns leading to obesity. Diabetes mellitus has played a crucial role causing nearly 14% of all deaths. We
wanted to make a comprehensive study of the role of diabetes in terms of burden of disease, prevalence, cost of
diabetes, cost of complications and health policy.
Method: We review the quantitative data that provides evidence of the extent to which the Mexican health
economy is affected by the disease and its complications. We then discuss the current situation of diabetes in
Mexico with experts in the field.
Results: There was a significant increase in the prevalence of diabetes from 1994 to 2006 with rising direct costs
(2006: outpatient USD$ 717,764,787, inpatient USD$ 223,581,099) and indirect costs (2005: USD$ 177,220,390), and
rising costs of complications (2010: Retinopathy USD$ 10,323,421; Cardiovascular disease USD$ 12,843,134;
Nephropathy USD$ 81,814,501; Neuropathy USD$ 2,760,271; Peripheral vascular disease USD$ 2,042,601). The health
policy focused on screening and the creation of self-support groups across the country.
Conclusions: The increasing diabetes mortality and lack of control among diagnosed patients make quality of
treatment a major concern in Mexico. The growing prevalence of childhood and adult obesity and the metabolic
syndrome suggest that the situation could be even worse in the coming years. The government has reacted
strongly with national actions to address the growing burden posed by diabetes. However our research suggests
that the prevalence and mortality of diabetes will continue to rise in the future.
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Mexico has been the subject of an epidemiological
transition: in two decades, Mexico’s disease profile has
transformed from malnutrition, communicable infec-
tious and parasitic diseases to a country dominated by
obesity, diabetes and other nutrition-related non-
communicable diseases (NR-NCDs) [1-3]. Mexico has
experienced some of the most rapid shifts in dietary and
physical inactivity patterns--and ultimately obesity--ever* Correspondence: icampos@insp.mx
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reproduction in any medium, provided the orrecorded [4-7]. Between 1988 and 2006, Mexico’s annual
prevalence rate of obesity (body mass index [BMI] ≥
30 kg/m2) increased among adults by approximately 2%
per year, the largest increase documented worldwide.
From 1980 to 2000 researchers documented an alarming
47% increase in diabetes mellitus mortality rates: in 1980
diabetes mellitus was the ninth cause of mortality and
ascended to the third by 1997 [2]. Based on national
mortality statistics, after disaggregating cardiovascular
disease, diabetes has been the primary cause of death
among women and men since 2000 followed by coron-
ary heart disease. In 2009, diabetes was responsible for
77,699 deaths, representing 13.76% of all deaths [8].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Prevalence of Diabetes mellitus
Survey Prevalence Women/Men Urban/Rural
1994 (ENEC-1994) 6.7% 6.8%/6.6% –
2000 (ENSA-2000) 7.5% 7.8%/7.2% 8.2%/5.6%
2006 (ENSANUT-2006) 14.4% 13.2%/15.8% 15.5%/10.4%
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In this paper we review the quantitative data that
provides evidence of the extent to which the Mexican
health economy is affected by the disease and its
complications. We then examine and discuss the current
situation of diabetes in Mexico with experts in the field.
Our research does not involve human intervention or
collection biological samples. This paper only describes
information of secondary databases and studies that have
been ed by Ethics, Research and Biosecurity Committees
of the National Institute of Public Health.
Results
Burden
In México, it was estimated in 2004 that NR-NCDs
caused 75% of the total deaths and 68% of total
disability-adjusted life years (DALYs). The leading causes
of death were ischemic heart disease, diabetes mellitus
and cerebrovascular disease. High body mass index
(BMI), high blood glucose and alcohol consumption are
responsible for a larger burden of disease than other non-
communicable disease risks; diabetes mellitus accounted
for 9.7% of total deaths, with higher percentages in women
(12.1%) than men (9.7%) and 3.5% of total DALYs. High
blood glucose and high BMI together accounted for 25.3%
of total deaths and 10.1% of total DALYs [9].
The country shows very heterogeneous levels of transi-
tion by region, a condition that has been called the
polarization of the nutrition/epidemiological transition; the
southern region of Mexico, which is less developed, showed
an increase of diabetes mortality rates from 1980–2000 of
128% compared to the more developed northern region,
where mortality increased only 32.5% [2]. The southern
region also faces higher prevalence of undernutrition and
infectious diseases making this region the one with the
largest burden of ill health in the country [9].
Sources of information: diabetes registers and national
surveys
Although there have been some efforts to develop a na-
tional registry of diabetes, this has not been accomplished
yet. The prevalence of diabetes and other diseases at the
national, regional and state level have been obtained from
diverse national surveys (the National Chronic Disease
Survey 1994, the National Nutrition Survey II and National
Health Survey 2000) which recently have been consolidated
into the Mexican National Nutrition Survey (ENSANUT
2006 and 2012) collected every six years. A representative
subsample of fasting serum, blood sugar, blood lipids,
and other biochemical indicators [10] is obtained from
participants 20-years and older. These surveys also collect
HbA1c from participants that have been previously
diagnosed to evaluate control. It also has a section on
access to health services. Data on expenditure onmedications for diabetes, high blood pressure and
obesity and treatments is collected by the National
Income and Expenditure Surveys every two years in
Mexico by INEGI [11]. Incidence data has been
collected from diverse cohorts such as the Mexico City
diabetes study, but how representative it is of the
entire country is uncertain [12]. Overall, the health
statistical system in Mexico has been recognized as
one of high quality, mostly due to the Mexican Health
and Nutrition Survey. However, as in many other
countries, incidence information is scarce [13].
Finally, together with the launch of the medical specialties
systems (UNEMES), there was an effort to establish an in-
formation system for diabetes outcomes, especially related
to quality of care indicators. However this system is still in
its development. Besides this, other local efforts have been
developed in the Mexican institute of social security (IMSS)
and within the certification of diabetic groups, that also
might be a reliable source in the near future [14].
Prevalence
There was a significant increase in the prevalence of
diabetes from 1994 to 2006 (the time frame covered by
the National Health Surveys). In the ENEC-1994 survey,
the prevalence of diabetes mellitus type 2 was 6.7%
(previously diagnosed [PD] 4.6% and newly diagnosed
[ND] 2.1% or didn’t know who they had diabetes). In
the ENSA-2000 study, the overall prevalence was 7.5%
(5.8% previously diagnosed and 1.7% newly diagnosed).
In the ENSANUT-2006 survey, the prevalence reached
14.4% (7.3% PD and 7.1% ND) (Table 1) [15]. The
prevalence increased in both genders. For women, the
prevalence was 6.8%, 7.8% and 13.2% in the 1993, 2000
and 2006 surveys respectively. The corresponding
percentages were 6.6%, 7.2% and 15.8% in men.
In both the ENSA-2000 and ENSANUT-2006 surveys
(the only two surveys with representation within rural
and urban areas), the prevalence was higher in urban
(8.2 vs. 15.5% respectively) populations compared to
rural ones (5.6 and 10.4% respectively). The estimated
overall prevalence of type 2 diabetes between 1993 and
2006 increased by two-fold (7.4 percentage points [pp]),
resulting in a rate of 0.56 pp/year. Considering only the
PD cases, the prevalence increased from 4.6% in 1993 to
7.3% in 2006. This is an overall increment of 2.7 pp over
a 13 year time period (0.2 pp/year).
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available in Mexico; the Mexico City study conducted in a
low-income population reported a cumulative incidence of
9.12% and 7.22% in males and females respectively, from
35–64 years of age in a 6.3 year follow-up [16]. A study in
Mexican-Americans showed a similar diabetes incidence of
6.5% after a 8-year follow-up, with higher rates for males
than females [17].
Diabetes mellitus prevalence has reached 14.4% of the
population (representing 7.31 million adults) [18] and at
the same time it has become the number one general
cause of mortality, with 14% of total deaths; in 2008 a total
of 75,572 Mexicans died from this cause (un-adjusted
mortality rate 70.8/100,000 inhabitants) [19,20].
Health care system
The Mexican health care system is formed by diverse
public institutions that offer health care services to both
the uninsured population (Ministry of Health Medical
Services) and salaried workers from the tax-paying
formal economy (Mexican Institute of Social Security
(IMSS) and the Institute for Social Security and Services
for State Workers (ISSSTE)). In 2001, Seguro Popular
(People’s Insurance) was created by the federal government
as a major effort to protect the uninsured population
against steep health care costs. Enrolment in Seguro
Popular is voluntary and is not dependent on health status
or pre-existing illness. There is no co-payment and
contributions are determined solely by ability to pay
[15], with a predefined quote based on income deciles
(the poorest 4 deciles of income without any payments
and from the 5th to the top income deciles a quote of
USD $152.00 to USD $834 per family per year) [21].
The rest of the population with purchasing power
receives medical attention from the private sector [22].
In its last report from 2010, the Seguro Popular had
already enrolled 43.5 millions of previously uninsured
Mexicans reaching 88.5% of the final goal of universal
coverage. The total contributions from family quotes
was USD$ 15.5 million, only covering a 0.2% of the total
financial sources that for the year 2010 resulted in USD
$ 8,043 million [21]. Diabetes mellitus is among the
many diseases covered by this insurance, however this
coverage includes mainly ambulatory primary care and
urgent care, but major costs of chronic complications
such as substitution of renal failure and acute coronary
syndrome was not covered in 2010. In 2011, myocardial
infarction was added to the catalogue of major diseases
covered, but only among adults younger than 60 years
old [23].
Costs of diabetes and costs of complications
Several estimates have been published about the economic
burden imposed to the health system by this condition. Inthe most recent published report, Avila et al. estimated the
total national expenditure on diabetes mellitus, cardiovas-
cular disease and obesity in 2006 came to USD$ 2,869.6
million representing 7% of the national health expenditure
and 0.4% of the Gross National Product (GNP). From this
amount 73% was financed by the state and 27% by the
private sector. A total of 40.7% of this estimate was
allocated solely to diabetes mellitus [11,24]. In addition
to this estimation, which is based on expenditure rather
than costs, many other cost estimates have been published
in the last two decades (Table 2).
Direct costs of diabetes
In a report published in 2006, the total cost for Diabetes
Mellitus in the country was USD$ 1,164.8 million
dollars, this amount includes the concepts described in
Table 3 [11].
These estimates are higher than the ones reported by
Arredondo et al. (2005) using different methodology
[22], where the total direct and indirect cost amounted
to USD$ 317,631,206 (see III. Discussion). A recent update
by this group found total costs for 2010 came to USD$
343,226,541 reflecting an increase of approximately 8% in a
5-year period [25].
Indirect cost of diabetes
In 2005 indirect costs were estimated at USD$ 177,220,390
(at an exchange rate corresponding to January 2003). From
these costs, a major part was the cost of permanently
disabled patients (USD$ 166,693,502), followed by the cost
of mortality (USD$ 8,010,360), and the cost of temporarily
disabled patients (USD$ 2,516, 528) [22].
Costs of diabetes complications
The main chronic complications of diabetes are
nephropathy, cardiovascular disease, retinopathy, neur-
opathy and peripheral vascular disease. Total annualized
average diabetes costs (without complications), is equivalent
to $707 US DLLS. When complications appear, this cost
increases by 75% when nephropathy is present, 13% for
vascular complications, 3% for neuropathy and 8%
for retinopathy.
Based on data from the 2006 health survey and with
the use of a predictive model, it is estimated that the
53.8% of people currently living with diabetes will die in
the following 20 years. The average life expectancy is
10.9 years (95% CI 10.7-11.2). It is expected that over
the next 20 years, 889,443 new cases of patients with
heart failure (95% CI 509, 638–1, 269, 248), 2,048,996
with myocardial infarctions (95% CI 1,699,743-
2,398,248), 798,188 with strokes (95% 544, 809–1, 051,
568) and 491,236 with lower-limb amputations (95% CI
313, 900–668, 572) will occur if the quality of care has
not been improved (Table 4).
Table 2 Cost of diabetes care in Mexico (in US dollars)
Source Year Methodology Coverage Direct cost Indirect cost Total cost
Philips M et al. 1992 Not specified Nationwide 99,936,000 330,000,000 429,936,000
Villarreal et al. 2000 Not specified Nationwide 2,618,000 Not specified Not specified
Barcelo et al. 2003 National databases Nationwide 1,974,200,000 13,144,100,000 15,118,200,000
Arredondo et al. 2004 Surveys, estimation of the mean cost of a typical case Nationwide 140,410,816 177,220,390 317,631,206
Zhang et al. 2010 Simulations Nationwide 4,836,480,000 Not specified Not specified
Rodriguez et al. 2011 Simulations, estimation of the mean cost of a typical case IMSSS 452,064,988 Not specified Not specified
Arredondo et al. 2011 Surveys, estimation of the mean cost of a typical case Nationwide 343,226 435,200,934 778,427,475
Modified from: Rodríguez Bolaños RA, Reynales Shigematsu LM, Jiménez Ruíz JA, Juárez Márquez SA, Hernández Ávila M. Costos directos de atención médica en
pacientes con diabetes mellitus tipo 2 en México: análisis de microcosteo. Rev Panam Salud Publica. 2010;28(6):412–20.
Table 4 Major diabetes complications and their direct
costs in Mexico
Direct costs attributable to diabetes
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complications from 2005 to 2010 can be explained by
three main reasons:
■ Despite promotion and prevention programmes for
complications of diabetes, epidemiological incremental
changes generated significant increases in demand for
care for diabetes complications.
■ Costs from 2005 to 2010 are steadily increasing.
■ Possible changes in the organization of health
systems in relation to the combination of inputs to
meet the health care required for the five major
complications of diabetes.
Diabetes prevention, screening and treatment and
outcome
Prevention
Since 2001, there have been explicit national diabetes
action programmes and the National Health Plan had an
important focus on NCDs [26]. During the 2007–2012
federal administration, NCDs became a top priority in
the National Health Plan [27], and efforts in prevention,
treatment and control were intensified based on a
specific action programme for diabetes mellitus [28].
Some of the important achievements in diabetes prevention
and control developed by the Ministry of Health (MOH)
and the public health services since 2000 are described
in Table 5.
One important success in this period was the creation
of self-support groups across the country. Currently
there are more than 11,000 groups receiving orientation,Table 3 Direct costs of diabetes (2006) [11]




Public Health Programmes $151,779
Health Administration and Medical Insurances $473,673guidelines and certification from the MOH. Screening
has also improved substantially; in 2000, 10% of adults
requested this service from the MOH. Six years later,
one out of every five adults went to public medical
services for blood glucose screening [28].
Screening
Currently, screening is based on an opportunistic strategy
with sporadic population base campaigns. The MOH
established a combined strategy of diabetes and hyper-
tension screening using an adaptation of the ADA
questionnaire and strategy in the case of diabetes [29].
However its validity has been considered questionable
because of its specificity.
Treatment
A recent report found that adequate control is very rare
for members of the population that participated in
ENSAUT 2006 that were previously diagnosed with
diabetes; only 6.6% of those diagnosed had HbA1c <7%.
One of the identified reasons for this increase in mortality
and lack of control has been the suboptimal efficacy of the
current therapeutic model. In addition, this report found
that most of the known diabetes population in Mexico are
in poor control, regardless of access to care, type of
institution, or insurance [30].complications in US dollars*
2005 [22] 2010 [25]
Retinopathy 4,968,491 10,323,421
Cardiovascular disease 4,516,810 12,843,134
Nephropathy 32,972,722 81,814,501
Neuropathy 1,626,050 2,760,271
Peripheral vascular disease 1,084,033 2,042,601
* 2005 estimates were for the three main public institutions of the Mexican
health care system; 2010 estimates included private costs and
private insurances.
Table 5 Recent government actions to prevent and
control diabetes [27,28]
1. Development of massive communication programmes to raise
awareness of the disease and of the benefits of healthy weight,
adequate diet and physical activity.
2. Regulation of food distributed in Mexican primary schools.
3. Launch of massive self-care diabetes campaigns.
4. Unification of guidelines and criteria to diagnose and control
diabetes.
5. Development of self-support groups for diabetic patients.
6. Strengthening of knowledge and competences for health
personnel and improvement of access to information by
the health sector and general population.
7. Development of a National Health Card for adults (similar to the
children vaccination card), in which criteria and objectives for
health risks are prioritized and evaluations of healthy weight,
blood sugar, blood pressure and lipids are emphasized.
Table 6 Drugs included in the basic scheme used to treat
diabetes
1. Glyburide, pioglitazone, rosiglitazone, metformin, acarbose.
2. Intermediate action human insulin NPH
3. Rapid action regular human insulin
4. Intermediate-slow action human insulin
4. Lispro insulin
5. Lispro protamine
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to lack of access to health services The majority of
patients are under treatment (94.1%), which is based on
the use of glucose lowering drugs in most cases (84.8%).
However, only a minority understands the importance of
life style modifications, e.g. the eating habits (24.1%) and
exercise (1.8%) as part of its management.
The use of insulin is delayed and it is indicated in a
small number of cases (6.8%) compared to international
standards (> 20%) The same phenomenon occurs with
other clinical variables that should be modified for the
prevention of chronic complications.
Half of the people with diabetes have high blood
pressure Among those previously diagnosed cases, 80%
received treatment. However, the majority (76.7%) has
blood pressure values above the recommended targets
(130/85 mmHg). The same phenomenon can be seen
with the treatment of dyslipidemia (DM) and the use of
antiplatelet drugs.
Other NR-NCDs in Mexico follow the same pattern of
DM; obesity is steadily increasing as well as high blood
pressure and other NR-NCD mortality causes such as
ischemic heart disease. Cardiovascular and liver diseases
are on the increase too [7,31]. In terms of insulin use,
many potential barriers have been proposed by the
attending physician, the patient and the institution itself.
However, recent efforts in public institutions are focusing
on how to increase insulin use among diabetics [32]. In
Mexico, public health services are obliged to provide all
prescribed medications to patients if included in the basic
medication scheme (a list of generic drugs). When a
prescribed medication is not on this list, it must be
purchased by direct payment by the patient in a drug store
or with charge to the institution, when it is justified
according to specific criteria [33].Some evidence of availability of drugs from the basic
medication scheme (Table 6) in primary health services
has been documented [34].
The increasing diabetes mortality and lack of control
among diagnosed patients make quality of treatment a
major concern in Mexico. The growing prevalence of
childhood and adult obesity and the metabolic syndrome
suggest that the situation could be even worse in the
following years [1,8,35,36]. An analysis of diabetes care
in the Mexican population using data from ENSANUT
2006 reported that 25.6% of the previously diagnosed
cases did not have access to care; from this percentage
73.4% were females and this group had the highest
proportion of subjects speaking an aboriginal dialect and
living in rural areas. This study showed that 85.6% of
diagnosed patients are treated with oral agents, 6.2%
reported no pharmacological therapy and a very small
proportion of the population was using insulin (as a single
therapeutic agent or in combination). Only a small
fraction of the participants had adequate HbA1c levels
and the group with no access to health care had similar
values of mean HbA1c compared to the rest of the groups.
A total of 84% of the population with HbA1c was poorly
controlled and more than half of these had levels above
12% [30]. Among the factors that were associated to a
better control in this survey were: a medical consultation
within the last three months, and access to social security.
The participation of a dietitian in the medical attention of
the participant decreased the odds of being severely
uncontrolled (RM= 61, 95%CI = 0.38-0.97) [37].
There are different sets of guidelines and norms in
Mexico, however recently an attempt to unify criteria has
been made. The NOM (Mexican Official Norm) NOM-
015-SSA2-1994 described the general treatment for diabetes
in medical practice. A new norm has been released with
more updated criteria in 2010 (NOM-015-SSA2-2010). The
UNEMES-Crónicas (previously described), have protocols
for interdisciplinary treatment of diabetes mellitus and
other diseases [38]. IMSS, ISSSTE and other public
health services have their own guidelines. There is also
consensus in publications from medical societies promoting
recommendations for DM treatment as well as position
papers [39,40].
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Each Mexican health system has his own set of diabetes-
related outcomes. However, their databases are not
integrated into a national registry. Outcomes are recorded
for all hospitalized patients by the attending physicians;
data is sent to a central office. However, outcomes are not
recorded in the majority of the outpatient clinics (except
for the UNEMES chronic units). Process indicators are
recorded in some but not in all health systems. Their
recollection started in the last five years.
Discussion
Weak evidence base due to lack of solid data
Data basis
Currently the major registry is within each public
institution, especially IMSS and ISSSTE, and its primary
use is administrative. Periodically the Minister of Health
reports on the number of diabetics registered as new
cases and estimates of incidence rates. However, due to
the lack of a diabetes registry, these estimates are not
often used for epidemiological or administrative purposes.
Moreover, since the year 2000, the MOH has started
another sentinel surveillance system for hospitalized cases
of diabetes but similar to the periodic surveillance reports,
the data obtained lacks validity for any systematic use. The
last report from this system was in 2007 [41].
In addition to the information system, Mexico has a
very well developed system for reporting mortality and
prevalence information based on national surveys. In
Mexico, date on diabetes mellitus mortality is obtained
from the National Mortality Statistics Registry managed
by the National Institute of Statistics, Geography and
Informatics (INEGI www.inegi.org.mx).
Prevalence data
There are multiple reasons for the observed changes in
the prevalence of diabetes. These include a shift in the
age distribution of the population and a growing
prevalence of obesity, principally related to changes in
lifestyle. However there are several methodological
differences between surveys that might explain part of
the ascendant trend. The proportion of subjects studied
under fasting conditions was small in both the 1993 and
2000 surveys (≈5%). As a result, most of the newly
diagnosed cases were identified by the random blood
glucose criterion (200 mg/dl). This characteristic of the
1993 and 2000 studies may have led to an underestimation
of the true prevalence; random glucose measurements are
the diagnostic criterion with the lowest sensitivity. This
was not the case for the ENSANUT-2006 survey. Fasting
was verified in all participants of the subsample in which
the prevalence of diabetes was estimated.
Another indicator of a possible underestimation of the
type 2 diabetes prevalence in the two earlier surveys is theproportion of previously diagnosed to newly diagnosed
cases. This ratio was 1:0.45 for ENEC-93, 1:0.26 for
ENSA-2000 and 1:0.97 for ENSANUT-2006 respectively.
The PD:ND ratio in the National Health and Nutrition
Examination Survey of North America (NHANES-III) was
1:0.5 [21]. The high prevalence of diabetes mellitus is
associated with an earlier age of onset in the majority of
the population [9]. The prevalence of type 2 diabetes
diagnosed before the age of 40 increased progressively
from 1.8% (PD = 0.95%, ND = 0.65%) in 1993 to 2.3%
(PD = 1.19%, ND = 1.51%) in 2000 and to 5.7% (PD =
1.45%, ND = 4.26%) in 2006. The surge of early onset
diabetes seen in ENSANUT-2006 corresponded pre-
dominantly to cases diagnosed during the survey.
Individuals diagnosed before the age of 40 will have a
longer exposure to hyperglycemia and other diabetes-
related abnormalities, ultimately increasing the likelihood
of chronic complications. Also, this type 2 diabetes will
require insulin therapy early on. Studying this variant of the
disease will render strategic information for health care
planning in Mexico; detection campaigns and preventive
actions have to be targeted to subjects younger and older
than 40 years. However, this strategy has to be proven to be
cost effective in order to establish it as a public policy.
Costs of diabetes – methods
Large differences exist between reports on costs; incon-
sistencies arise due to the sources of information used
and the assumptions and models applied. Depending on
the study referred to, these differences can be further
explained by one or more of the following reasons:
■ The population base and the method of costing may
be based only on estimates and probabilistic
simulations without information on actual costs or
actual cases from national health system.
■ The population base and the method of costing may
be based on actual costs and actual cases by type of
institution for the entire national health system.
■ The concept of costs and expenses are different;
some studies are not explicit or clear in regards to
expenditure or cost depending on the sources of
information and the type of inputs and costs.
■ In the case of the methodology based on annual
average cases, differences in the amounts are explained
by differences in the type and quantity of inputs used
by each institution depending on the production
function in question and the quality standards attention
as intervening variable in the control or management
cost average. This kind of estimate is more related to
the “ideal” cost, rather than the actual cost. For
instance, the differences in the total amounts of direct
and indirect costs can also be explained by differences
in the sources of cost information. Furthermore, the
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institutions, for public assistance and private
institutions and users.
Treatment
The lack of effectiveness of treatment is explained by
factors attributable to the health system, the doctor and
the patient. Although Mexican guidelines for the
treatment of diabetes exist, few doctors are familiar with
them or apply them. In addition, primary care clinics
(responsible for the treatment of the majority of the cases)
do not have the infrastructure to treat chronic diseases.
Diabetes management involves a learning process to
understand the disease, the changes needed in behavior,
the use of multiple drugs, the frequency of evaluations as
well as the participation of specialists in conjunction with
the family and the community. However, the current
organizational structure and procedures of the majority of
health institutions are not prepared to provide it.
Visits between doctor and patient are seldom
programmed. The duration of individual consultations is
insufficient and the inclusion and participation of other
health professionals only occurs in a few instances.
At present, the training of health professionals does
not adequately prepare them for the realities of practice.
Educational programmes provide a priority to combat
degenerative diseases in the medium term; however,
many graduates have the knowledge but lack the skills to
promote an effective treatment. As a result, clinical inertia
is a major contributor to the inefficiency of the system.
Finally, public awareness of the disease is low. Patients
often do not understand the treatment goals and do not
make the necessary lifestyle changes.
Programmes to improve the quality of diabetes treatment
have been presented but poorly implemented. The lack of
infrastructure of the teams in charge of the programmes is
the main reason for the lack of success.
Conclusions - health policy
The government has reacted strongly with national
initiatives to address the growing burden posed by diabetes.
However our research suggests that the prevalence and
mortality of diabetes will continue to rise in the coming
years. A national programme for adult and elderly health
integrates efforts for diabetes prevention, education and
control at the federal Ministry of Health. In addition,
the federal administration launched a system of primary
health clinics focused on the treatment of obesity,
diabetes mellitus, dyslipidemias and high-blood pressure
(UNEMES cronicas), with an interdisciplinary team
(comprised of a psychologist, social worker, dietitian, nurse
and physician) [42]. These clinics developed improved
guidelines for prevention, detection and control of NCDs
with an important behavioural component. They also areusing technology to optimize attention and improve
monitoring and evaluation.
This model is based on experiences in Ireland, London,
the US and Europe [43-46]. More than 50 clinics are now
operating in most states of the country. Information and
evaluations of this pilot programme would be useful to
quantify the potential impact of these initiatives. These
clinics are able to treat 3,000 patients/year. There is at least
one of the almost 100 UNEMES specialized health clinics
in the majority of states in Mexico.
There are additional government initiatives that set
out to complement the diabetes programme. Primary
care physicians and members of the “UNEMES cronicas”
teams are trained in virtual courses (diploma) in chronic
diseases (including evaluation and prescription of diet
and physical activity, obesity, diabetes, dyslipidemias and
high blood pressure treatment and adherence, and
motivational interviewing training coordinated by the
National Institute of Public Health for approximately
2,000 health professionals).
The MOH created a National Council for the Prevention
and Control of Chronic Diseases and promoted a
nation-wide communication programme called “Five
Steps for Your Health” (“Cinco pasos por tu salud”).
This programme included recommendations to consume
water (instead of soft drinks or other caloric beverages),
increase physical activity, increase consumption of fruits
and vegetables, and regular weight checks. A total of six
television advertisements on 440 television channels and
750 radio stations are broadcasted daily promoting this
programme which reaches an audience of approximately
70 million people [47].
During 2010, The president of Mexico announced that
the MOH together with the National Institute of Public
Health had developed the first national policy to prevent
obesity and promote healthy nutrition [48]. In addition to
these federal efforts, there are several state programmes to
prevent diabetes. IMSS, ISSSTE and other public health
services have developed their own national programmes
based on common guidelines. In a propensity score
matching analysis, poor diabetic patients registered with
Seguro Popular (part of the social health protection system)
showed in a preliminary analysis that they had improved
access to health care and blood glucose control [15].
Recommendations: priorities for the future
1. There is an urgent need to obtain evaluations of the
current preventive and control actions taking place
in the country.
2. More resources must be directed to diabetes
prevention and on translational research; currently
it represents only a minor amount of the total
diabetes costs.
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http://www.globalizationandhealth.com/content/9/1/33. Multidisciplinary teams should be available in every
primary care unit.
4. Primary care physicians should be re-trained to
improve their abilities to manage chronic
diseases. Certification programmes are urgently
needed for the diabetes related competences.
Additional internists, endocrinologists and other
specialists involved in diabetes care should be
incorporated into the various Mexican health
systems, although a focus on primary care should
be the top priority.
5. Programmes inmedical schools should focus on
improving the capabilities of their students to treat
chronic diseases.
6. Health systems should be re-organized to improve
the quality of the services provided. Certification
programmes for the diabetes units are urgently
needed. The use of electronic records (using the
same process indicators and outcomes) should be
implemented in all health systems.
7. Programmes designed to improve diabetes care in
Mexico should be coordinated by a full-time
dedicated multidisciplinary team with enough
resources to implement the required changes.
8. A diabetes national registry should be created.
9. Research and training for the adequate treatment
and control of diabetes should be increased in these
key areas: a) behavior modification, adherence and
motivation; b) nutrition and physical activity
evaluation, prescription and monitoring; and c)
evaluation, monitoring and pharmacological
treatment for health professionals.
10. There should be more regulations promoting a
healthy environment to facilitate the adoption of
healthy lifestyles:
■ regulate food and beverage marketing to children
and adolescents;
■ provide incentives for increasing consumption of
fruits and vegetables;
■ develop a government food and beverage front-of
-pack labeling system to promote healthier choices
among the population and incentivize the food
industry to reformulate and develop healthier
products;
■ invest in nutrition education and physical activity
promotion; and
■ promote water consumption as the preferred
hydration alternative.
11. Information systems need to be improved in order
to obtain precise incidence information.
12. Laboratory systems should be upgraded for the
adequate monitoring of patients.13. New therapeutic drugs including insulin should be
made more accessible within the primary level of care.
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